However, application of more selective RET kinase inhibitors, e.g., Selpercatinib, can stem tumour progression29–31, and have already shown to improve disease outcome for patients with MEN2-associated advanced MTC, with reduced toxicity, although early reports demonstrate resistance is acquired in some patients31–37. This evidence concerns the gene RET and neoplasm.